Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC)

被引：0

作者：

Yeh, Celine ^{[1
]}

Harrold, Emily ^{[1
]}

Keane, Fergus ^{[1
]}

Sinopoli, Jenna Cohen ^{[1
]}

Foote, Michael Bonner ^{[1
]}

Cercek, Andrea ^{[1
]}

Yaeger, Rona ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3542

引用

页数：1

共 50 条

[41] Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus ipilimumab (IPI): CheckMate 142
Andre, T.
Overman, M.
Lonardi, S.
Aglietta, M.
McDermott, R.
Wong, K. Y. M.
Morse, M.
Hendlisz, A.
Moss, R. A.
Ledeine, J-M.
Tang, H.
Cao, Z. A.
Kopetz, S.
ANNALS OF ONCOLOGY, 2017, 28
[42] NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study-A randomized phase III study of atezolizumab (atezo) monotherapyversus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
Lima, Caio Max Sao Pedro Rocha
Yothers, Greg
Puhalla, Shannon L.
Sanoff, Hanna Kelly
Cohen, Deirdre J.
Guthrie, Katherine A.
Henry, Norah Lynn
Ganz, Patricia A.
Kopetz, Scott
Lucas, Peter C.
Blanke, Charles D.
Jacobs, Samuel A.
Hong, Theodore S.
Wolmark, Norman
Hochster, Howard S.
George, Thomas J.
Overman, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)-NRG-GI004/SWOG-S1610.
Overman, Michael J.
Yothers, Greg
Jacobs, Samuel A.
Sanoff, Hanna Kelly
Cohen, Deirdre Jill
Guthrie, Katherine A.
Henry, Norah Lynn
Ganz, Patricia A.
Kopetz, Scott
Lucas, Peter C.
Blanke, Charles David
Wolmark, Norman
Hochster, Howard S.
George, Thomas J.
Rocha Lima, Caio Max Sao Pedro
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[44] Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/ atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)-NRG-GI004/SWOG-S1610
Lima, Caio Max Sao Pedro Rocha
Yothers, Greg
Jacobs, Samuel A.
Sanoff, Hanna Kelly
Cohen, Deirdre Jill
Guthrie, Katherine A.
Henry, Norah Lynn
Ganz, Patricia A.
Kopetz, Scott
Lucas, Peter C.
Blanke, Charles David
Hong, Theodore S.
Wolmark, Norman
Hochster, Howard S.
George, Thomas J.
Overman, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[45] NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study-A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
Overman, Michael J.
Yothers, Greg
Jacobs, Samuel A.
Sanoff, Hanna Kelly
Cohen, Deirdre Jill
Guthrie, Katherine A.
Henry, Norah Lynn
Ganz, Patricia A.
Kopetz, Scott
Lucas, Peter C.
Blanke, Charles David
Wolmark, Norman
Hochster, Howard S.
Georgev, Thomas J.
Lima, Rocha Caio Max Sao Pedro
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[46] NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study-A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
Overman, Michael J.
Yothers, Greg
Jacobs, Samuel A.
Sanoff, Hanna Kelly
Cohen, Deirdre Jill
Guthrie, Katherine A.
Henry, Norah Lynn
Ganz, Patricia A.
Kopetz, Scott
Lucas, Peter C.
Blanke, Charles David
Hong, Theodore S.
Wolmark, Norman
Hochster, Howard S.
George, Thomas J.
Lima, Caio Max Sao Pedro Rocha
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS258 - TPS258
[47] Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)-NRG-GI004/SWOG-S1610
Overman, Michael J.
Yothers, Greg
Jacobs, Samuel A.
Sanoff, Hanna Kelly
Cohen, Deirdre J.
Guthrie, Katherine A.
Henry, Norah Lynn
Ganz, Patricia A.
Kopetz, Scott
Lucas, Peter C.
Blanke, Charles D.
Hong, Theodore S.
Wolmark, Norman
Hochster, Howard S.
George, Thomas J.
Lima, Caio Max Sao Pedro Rocha
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS231 - TPS231
[48] NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study-A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)
Lima, Caio Max Sao Pedro Rocha
Yothers, Greg
Jacobs, Samuel A.
Sanoff, Hanna Kelly
Cohen, Deirdre Jill
Guthrie, Katherine A.
Henry, Norah Lynn
Ganz, Patricia A.
Kopetz, Scott
Lucas, Peter C.
Blanke, Charles David
Wolmark, Norman
Hochster, Howard S.
George, Thomas J.
Overman, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[49] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Lenz, Heinz-Josef
Lonardi, Sara
Zagonel, Vittorina
Van Cutsem, Eric
Limon, M. Luisa
Wong, Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
Yang, Jing
Ledeine, Jean-Marie
Overman, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[50] Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.
Lenz, Heinz-Josef
Lonardi, Sara
Zagonel, Vittorina
Van Cutsem, Eric
Limon, Luisa M.
Wong, Ka Yeung Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Luppi, Gabriele
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
Yang Jing
Memaj, Arteid
Overman, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

← 1 2 3 4 5 →